leep-disordered breathing (SDB) represents a highly prevalent comorbidity in heart failure (HF) patients. Approximately 45% of stable patients with either heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction have moderate to severe obstructive sleep apnea (OSA) or central sleep apnea (CSA) (1,2), and this prevalence is even greater in patients with acutely decompensated heart failure (ADHF) (3). Although OSA was identified as an independent risk factor for the development of HF (4), CSA with Cheyne-Stokes respiration is usually attributed to the pathophysiology of severe systolic dysfunction. Several observational studies suggest that effective treatment of SDB in HF may translate into improved quality of life, cardiac function, and even survival (5-10). These studies suggest that cardiologists need to be prepared to screen, diagnose, and even treat SDB in HF patients.
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In this context, the study by Sharma et al. (11) This approach to address the important comorbidity of SBD in patients with HF was promising in the population studied and has some significant advantages.
Patients admitted with HF represent a "captive population," and this in-hospital period can be leveraged to perform these diagnostic screening tests. Thus, a simple overnight in-hospital photoplethysmography might be 1 method to screen for SDB in HF.
However, there are some additional considerations for this study. With a pre-test probability of more than 50%, one might argue whether pre-screening is of any additional benefit in this patient population. A patient's history, symptoms, and even questionnaire results do not identify or exclude SDB in an HF population with high sensitivity or specificity (12, 13) . By pre-screening HF patients using the STOP-BANG questionnaire (recalling that it is not a properly validated instrument), there might be a nonspecific bias in patient selection for further screening. We agree that whichever screening method is used, it needs to be validated against the gold standard of poly- 
